Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells

scientific article

Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1002426020
P356DOI10.1007/S00280-007-0580-Y
P698PubMed publication ID17874104
P5875ResearchGate publication ID5969068

P50authorAkira SakaiQ90254945
P2093author name stringMitsuo Ochi
Shoji Shimose
Tadahiko Kubo
Toshihiro Matsuo
P433issue1
P921main subjectdoxorubicinQ18936
bone neoplasmQ1328805
P304page(s)111-116
P577publication date2007-09-15
P1433published inCancer Chemotherapy and PharmacologyQ326137
P1476titleEfficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells
P478volume62

Reverse relations

cites work (P2860)
Q36907149Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
Q24594269Addition of pamidronate to chemotherapy for the treatment of osteosarcoma
Q36491357Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?
Q26771376Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma
Q34365891Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma
Q41143144Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors
Q27654261Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation
Q37577433Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Q37476433Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model
Q36514299The Current and Future Therapies for Human Osteosarcoma
Q26747239p38 MAPK Signaling in Osteoblast Differentiation

Search more.